according to a filing with the U.S. Securities and Exchange Commission
April 22, 2023
Trending News 🌥️
Jazz Pharmaceuticals ($NASDAQ:JAZZ) Plc is a biopharmaceutical company focusing on improving patients’ lives by identifying, developing, and commercializing transformational therapeutics to address unmet medical needs. According to a filing with the U.S. Securities and Exchange Commission, the company’s institutional investor, DekaBank Deutsche Girozentrale, reduced its holdings in Jazz Pharmaceuticals Plc by 13.5% during the fourth quarter. The filing did not provide any further detail as to the reason for the decrease, but it is likely due to the company’s performance in recent quarters.
Market Price
On Wednesday, the stock opened at $142.9 and closed at $145.1, a 1.1% increase from the preceding day’s closing price of $143.6. Despite the decrease in institutional investors’ holdings, the closing price of the stock saw a slight bump, suggesting that the market remains positive on the prospects of Jazz Pharmaceuticals Plc. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Jazz Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 3.66k | -224.06 | 3.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Jazz Pharmaceuticals. More…
| Operations | Investing | Financing |
| 1.27k | -446.23 | -529.49 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Jazz Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 10.84k | 7.75k | 48.81 |
Key Ratios Snapshot
Some of the financial key ratios for Jazz Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 19.2% | -7.3% | -2.3% |
| FCF Margin | ROE | ROA |
| 21.1% | -1.8% | -0.5% |
Analysis
At GoodWhale, we have conducted an analysis of JAZZ PHARMACEUTICALS‘s wellbeing. Our findings show that JAZZ PHARMACEUTICALS is a high risk investment in terms of both its financial and business aspects. We have also detected 4 risk warnings in the company’s income sheet, balance sheet, cashflow statement, and non-financial metrics. To gain a deeper understanding of JAZZ PHARMACEUTICALS’s performance, we encourage you to register on goodwhale.com and take a look for yourself. Our experts are always on hand to answer any questions you might have. More…
Peers
The company has a diversified portfolio of products in central nervous system, hematology/oncology, inflammation and other therapeutic areas. Jazz Pharmaceuticals‘ competitors include Nurix Therapeutics Inc, Incyte Corp, and Poxel SA.
– Nurix Therapeutics Inc ($NASDAQ:NRIX)
Nurix Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on harnessing the body’s own natural mechanisms to regulate protein function for the treatment of cancer and other diseases. The company’s lead product candidate is a first-in-class, orally available, small molecule inhibitor of the proteasome, which is in development for the treatment of relapsed or refractory multiple myeloma. Nurix was founded by Robert L. Gould, Ph.D. and Bruce A. Cohen, M.D. in December 2001 and is headquartered in San Francisco, CA.
– Incyte Corp ($NASDAQ:INCY)
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. The company’s market cap is 15.34B as of 2022 and its ROE is 9.54%. Incyte’s products include Jakafi, Iclusig, and Jakavi. Jakafi is used to treat myelofibrosis and polycythemia vera, two rare blood disorders. Iclusig is used to treat leukemias, including chronic myeloid leukemia andPhiladelphia chromosome-positive acute lymphoblastic leukemia. Jakavi is used to treat myelofibrosis, polycythemia vera, and essential thrombocythemia.
– Poxel SA ($LTS:0RA2)
Poxel SA is a French pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of diabetes and obesity. The company has a market capitalization of 43.37 million as of 2022 and a return on equity of -705.2%. Poxel SA’s products include Imeglimin, which is in clinical development for the treatment of type 2 diabetes, and PXL065, which is in preclinical development for the treatment of obesity.
Summary
Investment analysis of Jazz Pharmaceuticals Plc (JAZZ) has recently seen a significant change in its quarterly stockholdings. DekaBank Deutsche Girozentrale, one of the company’s largest institutional investors, reduced its shareholdings by 13.5% during the fourth quarter. Although the reasons behind the decision remain unclear, it may suggest that the bank has grown increasingly wary of the stock’s prospects or that it is shifting its portfolio toward other investments. Investors should keep an eye on the company’s future performance and any upcoming developments to better understand the impact of this divestment.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
